EMPOWER-ED was a two-arm, individually randomized trial with a 6-month follow-up conducted at Veterans Health Administration ...

Longer times from symptom onset to randomization equaled a smaller—or perhaps no—advantage for Impella vs standard care.

ZUG, Switzerland, July 25, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, ...

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 18 June 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company ...

The MajesTEC-9 trial showed a 40% reduced risk of death and a 71% reduced risk of disease progression or death with ...

MUNICH, Jan. 10, 2025 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC”), a clinical-stage precision psychiatry biopharma company pioneering personalized treatments powered by predictive companion ...

SAN FRANCISCO -- Patients with colon cancer and comorbid obesity treated with GLP-1 receptor agonists had lower mortality and ...

Mavacamten is a selective, reversible, allosteric cardiac myosin inhibitor. It is approved under the brand name Camzyos ® for the treatment of adults with symptomatic New York Heart Association class ...

Using Music as a Tool for Distress Reduction During Cancer Chemotherapy Treatment Future work should aim to improve patient adherence to remote patient-reported outcome and activity data collection ...

Immunocore (IMCR) announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous ...